Sagimet Biosciences Inc. (SGMT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
155 Bovet Road
San Mateo, CA 94402
United States of America (the)
Phone
650-561-8600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
July 14, 2023
| Name | Title | Pay | Year Born |
| David A. Happel | Chief Executive Officer, President & Director | 943,883 | 1962 |
| Thierry Chauche | Chief Financial Officer & Principal Accounting Officer | 598,045 | 1976 |
| Andreas Grauer | Chief Medical Officer | 669,064 | 1961 |
| Elizabeth Rozek | Chief Legal & Administrative Officer | 669,897 | 1972 |
| Marie O'Farrell | Chief Scientific Officer | 0 | N/A |
| Robert D'Urso | Senior Vice President of New Products | 0 | N/A |
| Lucas Pelkmans | Co-Founder | 0 | N/A |
| Urs Greber | Co-Founder | 0 | N/A |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.